OTOR antibodies are tools used to study the OTOR protein (also known as FAM11B or FcRL4), a member of the Fc receptor-like (FCRL) family. OTOR is primarily expressed in B-cells and certain epithelial tissues, where it modulates immune responses by influencing B-cell receptor (BCR) signaling and interactions with other immune receptors. Structurally, it contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs), suggesting a regulatory role in dampening B-cell activation. Dysregulation of OTOR has been linked to autoimmune disorders, lymphomas, and chronic inflammatory conditions, making it a focus in immunopathology research.
OTOR antibodies are generated as monoclonal or polyclonal reagents to detect the protein’s expression, localization, and post-translational modifications. They are critical for techniques like Western blotting, immunohistochemistry, and flow cytometry, enabling researchers to explore OTOR’s tissue-specific functions and pathological mechanisms. Recent studies highlight OTOR’s potential as a therapeutic target, particularly in diseases characterized by aberrant B-cell activity, such as rheumatoid arthritis or B-cell malignancies. However, its exact physiological roles remain under investigation, partly due to interspecies variability and complex signaling crosstalk. Validated OTOR antibodies thus serve as essential reagents to dissect its contributions to immune regulation and disease progression, bridging gaps in understanding its dual roles in homeostasis and pathology.